228MO PALOMA-4: Primary results from a phase III trial of palbociclib (PAL) + letrozole (LET) vs placebo (PBO) + LET in Asian postmenopausal women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative (ER+/HER2–) advanced breast cancer (ABC)

• DOI: 10.1016/j.annonc.2021.08.511
• Publication Date: 2021-09-21T18:44:24Z
• Authors: B. Xu; X. Hu; W. Li; T. Sun; K. Shen; S. Wang; Y. Cheng; Q. Zhang; S. Cui; Z. Tong; C. Geng; C-S. Huang; V. Sriuranpong; K.C.R. Ngan; Y.H. Chia; X. Wang; H. Zhao
• Keywords: Palbociclib; Letrozole